University of British Columbia

Eledon Pharmaceuticals will present updated clinical data from approximately 30 kidney transplant recipients in their ongoing Phase 1b study of tegoprubart at the World Transplant Congress in San Francisco.

Researchers developed liposomal lipid nanoparticles (LNPs) with high bilayer lipid content that exhibit enhanced mRNA encapsulation and transfection potency compared to conventional Onpattro-like formulations.

A population-based study of 3,004 inflammatory arthritis patients in British Columbia found no significant differences in healthcare utilization between those prescribed etanercept biosimilars versus originators following a 2017 policy mandate.

Zetagen Therapeutics has completed enrollment in a Phase 2a clinical trial evaluating ZetaMet™ (Zeta-BC-003) for treating spinal metastatic lytic breast cancer lesions, with results expected in Q4 2025.

• A Canadian multi-center study demonstrates that the 'Walk 'n Watch' protocol significantly improved walking distance by 43.6 meters compared to standard care in stroke patients. • The protocol, which implements 30 minutes of progressive intensity walking activities with heart rate and step tracking, successfully enhanced patients' quality of life, balance, and mobility. • Real-world implementation across 12 Canadian hospitals proved highly effective, with researchers noting immediate applicability in current healthcare settings.

• University of Calgary researchers are initiating a validation study for the Mira Hormone Monitor, a device claiming to provide precise numerical readings of hormone biomarkers from urine samples. • The study, requiring Health Canada clearance, aims to validate the device's claimed 99% lab-grade accuracy using ultrasound testing as the gold standard for comparison. • The technology could revolutionize women's healthcare by enabling daily hormone tracking for conditions like PCOS and PMS, while providing comprehensive data for healthcare providers.

• Women undergoing chemotherapy for breast cancer reported improved cognitive function when participating in an aerobic exercise program, according to the ACTIVATE trial. • The study found that patients who started aerobic exercise alongside chemotherapy experienced better self-reported mental abilities compared to those receiving standard care alone. • Objective neuropsychological testing showed similar cognitive performance between the exercise and standard care groups, but exercise still improved quality of life. • Researchers suggest integrating exercise assessment and referral into routine cancer care to support both physical and mental health during and after treatment.

• A comprehensive review of literature reveals significant disparities in biologic therapy access for psoriasis patients, including barriers related to race, age, socioeconomic status, and rural residence. • Research from the University of British Columbia found that 59% of insured patients with mild-to-severe psoriasis went untreated in the previous year, highlighting substantial treatment gaps. • Key barriers identified include specialist shortages, healthcare practitioner awareness deficits, patient discrimination, lack of standardized treatment protocols, and high therapy costs.